ITC-6102RO

News alerts, weekly reports and conference planners

Company:

IntoCell

Drug class:

DNA replication inhibitor, B7-H3-targeted antibody-drug conjugate

Related drugs:

‹

›

CD276 overexpression	Breast Cancer	CD276 overexpression	Breast Cancer	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D
CD276 overexpression	Lung Cancer	CD276 overexpression	Lung Cancer	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D

Associations
(2)